Deal Library / Pharma BD Deal Intelligence

Gilead Sciences Inc. — Pharma Deals

The Pharma Closeout tracks 26 deals, $93.3B in disclosed deal value, 17 with a post-close Outcome Score for Gilead Sciences Inc..

Median Critic Score: 83  ·  Median Outcome Score: 46

Best outcome: Gilead Sciences Inc. / Pharmasset Inc. (98)  ·  Weakest outcome: Gilead Sciences Inc. / YM BioSciences Inc. (17)

All 26 deals

• Gilead Sciences Inc. / Pharmasset Inc. — 2011 · $11.2B · Worked — the deal delivered on its rationale.
• Gilead Sciences Inc. / Triangle Pharmaceuticals Inc. — 2002 · $464M · Worked — the deal delivered on its rationale.
• Gilead Sciences Inc. / CymaBay Therapeutics — 2024 · $4.4B · Worked — the deal delivered on its rationale.
• Gilead Sciences Inc. / Nurix Therapeutics Inc. — 2019 · $2.3B · Largely worked — most objectives met.
• Gilead Sciences Inc. / Immunomedics Inc. — 2020 · $21.0B · Largely worked — most objectives met.
• Gilead Sciences Inc. / Kite Pharma, Inc. — 2017 · $11.9B · Largely worked — most objectives met.
• Gilead Sciences Inc. / CV Therapeutics Inc. — 2009 · $1.4B · Largely worked — most objectives met.
• Gilead Sciences Inc. / Myogen Inc. — 2006 · $2.5B · Largely worked — most objectives met.
• Gilead Sciences Inc. / Arcus Biosciences, Inc. — 2020 · $5.0B · Mixed — partial payoff, real shortfalls.
• Gilead Sciences Inc. / Calistoga Pharmaceuticals, Inc. — 2011 · $600M · Underwhelmed — fell short of the thesis.
• Gilead Sciences Inc. / Goldfinch Bio Inc. — 2019 · $240M · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / Galapagos NV — 2019 · $5.1B · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / Cell Design Labs, Inc. — 2017 · $567M · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / Nimbus Apollo, Inc. (Nimbus Therapeutics subsidiary) — 2016 · $1.2B · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / Galapagos NV — 2016 · $2.1B · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / Forty Seven Inc. — 2020 · $4.9B · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / YM BioSciences Inc. — 2012 · $510M · Did not work — the deal failed to deliver.
• Gilead Sciences Inc. / Ouro Medicines, Inc. — 2026 · $2.2B
• Gilead Sciences Inc. / Arcellx, Inc. — 2026 · $7.8B
• Gilead Sciences Inc. / Tubulis GmbH — 2026 · $5.0B
• Gilead Sciences Inc. / Interius BioTherapeutics, Inc. — 2025 · $350M
• Gilead Sciences Inc. / LEO Pharma A/S — 2025 · $1.7B
• Gilead Sciences Inc. / HOOKIPA Pharma Inc. — 2025 · $10M
• Gilead Sciences Inc. / Assembly Biosciences, Inc. — 2025 · $365M
• Gilead Sciences Inc. / Sprint Bioscience AB — 2025 · $414M
• Gilead Sciences Inc. / Tibotec Pharmaceuticals (Janssen) — 2011

← Deal Library  ·  Interactive search  ·  How we score deals